Patients with amblyopia who were treated with the CureSight eye-tracking system achieved greater improvement in visual acuity at week 16 vs. those treated with patching, according to a study published in American Journal of Ophthalmology.
“This important breakthrough in amblyopia treatment is a reflection of NovaSight’s innovative technology in addition to the patients’ willingness to adhere to the CureSight regimen, which is better than patching, to which adherence is generally less than optimal,” Tamara Wygnanski-Jaffe, MD, head of the pediatric ophthalmology and